Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus insulin strategies for ICU hyperglycemia
IRCT20220814055683N2Phase 3Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of empagliflozin and human insulin in hyperglycemia (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Glycemic control, Total daily regular insulin requirement and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
empagliflozinhuman insulin
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on IRCT20220814055683N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220814055683N2.